Tendon tissue engineering: An overview of biologics to promote tendon healing and repair

Introduction

Tendons are well-organized, dense connective tissues that respond and adapt to the transmission of contraction forces by muscles to the skeleton, allowing motion and maintenance of posture. ¹ Tendinopathies are common musculoskeletal disorders that affect a wide spectrum of society.

In tendinopathy, the pathological changes can be interpreted as a failure in the homeostatic response of the tendon ² to adapt to altered mechanical loading, resulting in permanent changes in the native tendon structures and mechanics.^2,3 At least three phases of tendinopathy have been hypothesized: reactive tendinopathy, tendon disrepair (failed healing) and degenerative tendinopathy. The continuum model for the pathogenesis of tendinopathy describes load-induced tendinopathy as a continuous evolution and readaptation of the tendon structure to the applied load. ⁴

In the reactive phase, short-term adaptation to the overload results in an increase in the size of the tendon, thus reducing stresses and increasing stiffness. The preliminary engagement of ground substance in this process explains the potentially temporary nature of this first adaptation. During the disrepair phase, the tendon tissue attempts to repair increasing the number of cells and consequently the production of proteins; the increase of proteins, such as proteoglycans and collagen, induces disassembling of the matrix. The terminal degenerative phase results in an irreversible stage of pathology in which the major structural and compositional changes, cell death, tissue breakdown and loss of function with the predisposition of the tendon to further injury and rupture occur. ⁵ The three main actors involved in tendon degeneration are mechanical overuse applied on the matrix, neo-vascularization via exogenous cells, and endogenous cell ageing. ⁶

Tendon healing is a complex coordinated event orchestrated by numerous biologically active proteins. ⁷ Adult tendons have a limited natural healing capacity and often respond poorly to current treatments focused on exercise, drug delivery, and surgical procedures. The incapacity of complete healing derives from the nature of the tendon with its low cellularity, low metabolism, and limited vascularization, which hamper the synthesis of extracellular matrix (ECM) ⁸ and results in scar tissue formation and fibrosis, accompanied by alterations in the biomechanical properties of the tissue. ⁹

The cellular component of the tendon is limited, and with age, it tends to diminish and change in morphology, with loss of stemness markers ¹⁰ as also seen with tendinopathy or acute trauma. Tenocytes are responsible for homeostasis and the maintenance of tendon structure and functionality. The resident stem cell population are called tendon stem cells (TSCs) and lie parallel to collagen fibrils surrounded by the extracellular matrix proteins fibromodulin and biglycan. ¹¹ As the tendon is a mechanosensitive tissue and extracellular matrix (ECM) remodelling is influenced by mechanical stimulation, prolonged rehabilitation is considered a valid alternative to surgery, as it offers great support and is more efficient than pharmacological therapy. ¹² Therefore, it is of great importance to identify key molecular and cellular processes involved in the progression of tendinopathies and in tendon response to them to develop effective therapeutic strategies and drive the tissue towards regeneration. ¹⁰ Unfortunately, the structural complexity and lack of understanding of this healing mechanism have been major obstacles to the development of current surgical methods and therapies.

The current promising approach to the development of therapeutics has been influenced by key principles from a variety of fields, such as biomechanics, developmental biology, cell and growth factor therapy, and tissue engineering. ¹³ It aims to reproduce a safe and successful long-term solution for full microarchitecture and biomechanical tissue recovery. These ‘biological’ treatments likely stimulate the repair and regeneration of damaged structures, limit scar tissue formation, and improve recovery and healing times. Commonly explored therapies for tendinopathies include platelet-rich plasma (PRP), stem cells/stromal cells treatments with the addition of soluble signals like growth factors, and most recently extracellular vesicles (EVs). ¹⁴

This review will cover the literature surrounding recent advances in tendon repair. It will transversally analyse the cause-and-effect relationship among biochemical, biological and structural properties of tendon development, providing a complete insight into the aspect to consider during the process of tissue engineering. It will first provide a general overview of tendon structure and function to be able to understand the physiological processes involved in tendinopathies. Then, current approaches for tendinopathies treatment will be shown, highlighting the future promise for tissue engineering in tendon regeneration. In this article, we focus on the potential of MSCs cells to differentiate into tendon cells and on the therapeutic roles of EVs for the promotion of tendon repair.

Tendon ontogeny

The ECM experiences limited turnover during the life span of an individual. ¹⁵ With age, aerobic energy production and synthesis of ECM components decrease. The shift to anaerobic metabolism allows tendons to tolerate low oxygen levels, reducing the risk of ischaemia and necrosis during extended periods of stress but also resulting in a poor and slow healing capacity.

To generate functional and self-renewing tendon tissue, it is necessary to understand the normal processes of tendon development. In particular, we need to understand which stem cell populations in the body are able to form tendons, how they can be directed to do so in culture excluding any other possible differentiation, and how their growth is controlled and monitored during the whole differentiation path.

Developmental biology of the tendon

Axial tendon progenitors and progenitors of the limb tendons develop differently. The vertebrate axial musculoskeletal system originates from somites: dorsally located segmental blocks of mesoderm in the embryo that lie adjacent to the natural tube and notochord. ¹⁶ The differentiation of the tendon in the somite depends on the combination of both activating and repressing signals from its different regions. Brent et al. localized a fourth region of the somite for the first time, between the sclerotome and the dermomyotome, which locates the basic-helix-loop-helix transcription factor Scleraxis (Scx) ¹⁷ As determined from previous studies,^17,18 removing the dermomyotome before myotome formation or silencing the myogenic genes, such as MyoD and Myf5, which hamper muscle formation, abolish Scx expression. Therefore, myotome signals are relevant for the activation of tendon differentiation in the syndetome. Nevertheless, several fibroblast growth factors (FGFs), are expressed in the myotome resulting in the activation of the mitogen-activated protein kinase pathway, transformation-specific sequence (Ets) transcription factors, Phosphatidylinositol-4-phosphate 5-kinase (Pea3) and Ezrin/radixin/moesin (Erm), all responsible for Scx upregulation. ¹⁹ The muscle precursor region of the somite is therefore essential for the initiation of tendon differentiation (Figure 1).

OPEN IN VIEWER

Figure 1.

Trunk tendon differentiation model. In the axial tendon, signals from the myotome are essential for the initiation of tendon progenitor cells, whereas signals from the sclerotome, which are activated by the ventral midline sonic hedgehog signal, in turn, play an opposite role. Scx and Mkx promote axial tendon differentiation by activating extracellular matrix molecules.

Conversely, the cartilage precursor cells of the sclerotome have an opposite role in controlling the specification of the tendon progenitors. The signal from the sclerotome activated by Sonic Hedgehog (SHH) expression, blocks Scx expression directly, through Pax1 activity, or indirectly by means of Sox5 and Sox6, which in turn, is induced by Sox9 (Figure 2). These genes are also essential in cartilage formation, with the Scx⁺/Sox9⁺ pool essential for the formation of the chondro-tendinous/ligamentous junction, which further develops into the osteo-tendinous/ligamentous junction, providing anchorage of the tendon to the muscles (Figure 3).

OPEN IN VIEWER

Figure 2.

Development of limb tendon in embryogenesis. In the limb, Scx and Sox9 are the first signals for tendon progenitor cell initiation, whereas Mkx and early growth response 1 and 2 are the second signals for tendon differentiation and maturation. Sox9 is involved in the initial stage and changes to play an opposite role subsequently. Both are synergically involved in limb tendon development by interacting with related growth factors.

OPEN IN VIEWER

Figure 3.

Expression of tendon markers in tenocytes during tendon development. (A) Mesenchymal cells differentiate into Scx-expressing tendon progenitor cells, which also partially express Sox9. Scx+Sox9+ progenitor cells differentiate into the tenocytes which are located near the bone in the enthesis. (B) In mouse limbs, Scx expression begins to increase at E9.5 and continues to increase until tenocyte maturation. Slight Mkx expression is detectable in the tendon at E12.5, after the emergence of Scx and robust Mkx mRNA expression at E13.5 and E14.5, stages at which the tendon progenitors undergo condensation and differentiation. Egr1 transcripts are first expressed at E12.5 in Scx domains forming tendons, and then they are expressed in long tendons at E16.5. Egr2 is first detectable in E14.5 limb tendons and is generally expressed in all limb tendons by E16.5. Tnmd is highly expressed in E14.5 and is considered a late tendon marker. Adapted from He et al. ²⁰ , 2022, reproduced under a Creative Commons CC-BY license, and from Fang et al. ²¹ , 2022, with permission from Elsevier Science.

Although the progenitors of muscle, cartilage and tendon arise in different compartments of the somite, the differentiation of tendons depends on a combination of both activating and repressing signals from the other two compartments. Progenitors of the limb tendons develop differently from the cells that give rise to axial tendons because they are not localized within a specific subdomain in the somite (Figure 3). The initiation of Scx expression in tendon progenitor cells in the limbs does not require signals from myogenic cells (including FGFs), but they are necessary for their continued differentiation. ²² Both FGF and TGFβ can induce tendon development. ²³ In particular, TGFβ signalling is important for the maintenance and recruitment of tendon progenitors in a paracrine or autocrine manner. ²⁴ Moreover, mechanical forces maintain the expression of Scx through TGFβ/Smad2/3 mediated signalling. ²⁵ Scx and Mkx play a pivotal role in providing the starting impulse for limb tendon formation. The expression of Mkx is detectable after the emergence of Scx, and its strongest expression is recognized in the sheath cells. ²⁵ The role of Mkx is essential for tendon growth regulation after tendon progenitor initiation during embryogenesis and is relevant for the regulation of the postnatal growth and maturation of collagen fibrils and other tendon-related proteins such as decorin, fibromodulin and lumican. ²⁶

Bone morphogenetic protein (BMP) family members, including growth and differentiation factors (GDF) isoforms GDF5, 6 and 7, also known as BMP14,13 and 12, have been implicated in tendon development ²⁷ and healing. The absence of these factors directly affects the biological and biomechanical cues of the neo-tendon. Of relevant importance is the mutual antagonism between BMP and FGF signalling: the activation of FGF inhibits BMP consequently promoting tendon formation, whereas the activation of BMP induces the FGF inhibition, resulting ultimately in chondrogenesis. ²²

These studies have highlighted specific growth factors and transcription factors involved in tenogenesis (Table 1) during developmental and repair processes. Although mechanical factors also seem to be essential for tendon development, understanding the link between the mechanical and biological parameters involved in tendon development, homeostasis and repair is a prerequisite for the identification of effective treatments for chronic and acute tendon injuries.

OPEN IN VIEWER

Table 1.

Growth factors and transcription factors involved in tenogenesis.

Gene	Category	Role	Phenotype under abnormal expression	Ref.
MKX	Transcription Factor	Tendon maturation and differentiation Maintaining TSCs characteristic	• Reduced Scx expression • Decrease of ColI, Fmod, Dcn • Small collagen fibres diameter • Tendon sheath is thicker • Increase amount of cells • Reduced tensile strength • Abnormal collagen fibril structure	Liu et al. 11 , Dale et al. 27 , Otabe et al. 28
SCX	Transcription Factor	Embryonic development of tendons induced with mechanical stimuli Early marker of tendon developmental and differentiation	• The tendon matrix results to be reduced and disorganized • Hypocellularity • Disorganized endotenon • Downregulation of Mkx • Reduced production of ColI	Liu et al. 11 , Ito et al. 29 , Gumucio et al. 30 , Mendias et al. 31 , Bagchi et al. 32
EGR1/2	Transcription Factor	Act as molecular sensors for mechanical signals and are involved in collagen maturation	• Reduced expression of Scx, Mkx, Tnmd and ColI • Tendon mechanically weaker and fragile	Ellingson et al. 24 , Huang et al. 33 , Guerquin et al. 34
TNMD	Glycoprotein	Later marker of tenogenesis Regulator of tenocyte proliferation and is involved in collagen fibril maturation but does not confirm an in vivo involvement of Tnmd in angiogenesis.	• Decrease tenocyte proliferation and density • Hypocellularity • Thicker collagen fibres • The deposited amounts of extracellular matrix proteins are not affected but they present a disorganized structure • Reduced self-renewal but increased senescence of mouse TSCs • Insufficient adhesion to collagen type I, and impaired ability to contract the extracellular matrix.	Lejard et al. 35 , Docheva et al. 36 , Yin et al. 37 , Liu et al. 36 , Alberton et al. 39 , Dex et al. 40
BGN	Proteoglycan	Control Scx expression Regulate collagen fibrillogenesis and extracellular matrix assembly in tendon	• Decreased tendon stiffness • Alteration of the collagen fibrils • Increased fibres diameter	Dex et al. 41 , Cohen et al. 42 , Gordon et al. 43 , Dunkman et al. 44
DCN	Proteoglycan	Regulate collagen fibrillogenesis and extracellular matrix assembly in tendon	• Dysfunctional regulation of fibril • Abnormal lateral association with other fibrils • Greater viscous properties • Reduction of collagen content • Reduced tendon strength • Increased stiffness	Gordon et al. 43 , Dourte et al. 45 , Roughley and Lee 46
COL1A1	Protein	Main structural protein and ECM component	• Fibril dimension decrease	Dourte et al. 47
COMP	Glycoprotein	Binding other ECM proteins, catalysing the polymerization of type II collagen fibrils, and regulating chondrocyte proliferation	• Chondrocyte cell death • Matrix is abnormal and easily erodes with normal physical activity	Löhler et al. 48 , Smith et al. 49
FBN1	Proteoglycan	Formation of elastic fibres found in connective tissue	• Decrease collagen cross-link	Geng et al. 50 , Giusti and Pepe 51
FMOD	Proteoglycan	Control Scx expression Required in early collagen fibrillogenesis to stabilize small-diameter fibril-intermediates	• Small diameter and immature collagen fibrils • Thinner collagen fibres • Non-crosslink • Reduced number of cells • Increase lumican	Dourte et al. 45 , Boregowda et al. 52 , Ezura et al. 53
LUM	Proteoglycan	Needed at a later stage, primarily to limit the lateral growth of fibrils	• Disorganized matrix • Large diameter collagen fibres	Boregowda et al. 52 , Ezura et al. 53 , Majava et al. 54
THBS-4	Glycoprotein	Late marker	• Disordered collagen fibrillogenesis	Zelzer et al. 55 , Bornstein et al. 56

Tendon structural and functional relationship

Tendon cells

Mature tendons are normally characterized by a low cellular density. Approximately 90%–95% of the cellular content of tendons comprises tendon-specific cell types described in the literature as tenocytes and tenoblasts. ⁷¹

Tenocytes, which are tendon-specific terminally differentiated fibroblasts, are spindle-shaped, with elongated nuclei and thin cytoplasmic protrusions anchoring the collagen fibres. They are laid between collagen fibrils and oversee the production of extracellular matrix (ECM) as well as the maintenance, repair, and remodelling of tendons. Tenogenic differentiation markers are commonly used for the identification of tenocytes. Tenoblasts are relatively round cells with large ovoid nuclei. Tenoblasts seem dominant in young tendons, and they transform into tenocytes during maturation and ageing. Interconversion between tenoblasts and tenocytes might occur, and their ratio in tendons may govern the tissue responses to various stimuli such as exercise and trauma. ⁷¹ Tenoblasts are sometimes regarded as an activated form of tenocytes, such as in intrinsic healing of tendon injuries; the discrimination between tenocytes and tenoblasts, which is based on cell shape appearance, lacks precise molecular separation via marker gene expression. ⁷² The remainder of cells in the tendon are mainly composed of chondrocytes at the pressure and insertion sites, synovial cells of the tendon sheath, capillary endothelial cells and smooth muscle cells of arterioles. ⁷²

Tendon cells synthesize all components of the tendon ECM with peak activity during growth and a gradual decrease during ageing. ⁷¹ It is thought that low metabolic rates associated with anaerobic energy production which is typical of mature tendon cells can reduce the risk of ischaemia and necrosis, especially during the extended periods of tensional stresses to which tendons are usually subjected. On the other hand, this feature is a disadvantage for tendon recovery and healing. ⁷⁰

Tendons also contain a pool of stem and progenitor cells. In 2007, Bi et al., ⁷³ identified within human hamstring tendons a novel cell population of resident tendon stem/progenitor cells (TSPCs). TSPCs exhibit classical adult mesenchymal stem cell (MSC) criteria such as the presence of specific surface antigens, self-renewal, clonogenicity and three-lineage differentiation (adipogenic, osteogenic and chondrogenic), ⁷⁴ and they express tendon-related genes such as scleraxis (Scx) and tenomodulin (Tnmd) and can form tendon and enthesis-like tissues when implanted in vivo. ⁷⁰ Recently, it was proposed that there is a regional distribution of different stem/progenitor cells within the tendon, namely in the outer tendon sheet (TSPC type I) and within the tendon proper (TSPC type II) ⁷³ (Figure 4). Comparison between these subpopulations revealed that the peritenon-derived cells have increased vascular and pericyte markers, while the tendon-proper-derived cells are more proliferative and exhibit higher levels of Scx and Tnmd. ⁷⁵ TSPCs can also be positive for some common stem cell markers, which can also be found on the surface of other mesenchymal stem cell (MSCs) types. They express Sca-1, CD44, CD90, CD90.1, CD105, CD146, Stro-1, nucleostemin, Oct-4 and SSEA-1 but not CD18, CD31, CD34, CD45, CD106, CD117, CD144 or Flk-1. ⁷⁶ Since there are no molecular markers that allow discrimination between TSPCs, tenoblasts and tenocytes (Figure 5), it is not easy to isolate pure subsets of cell populations from these differentiation stages. ⁷⁴ Ruzzini et al. ⁷⁷ isolated tendon-derived CD44+ cells, which were positive for the stem cell markers CD146 and STRO1 and reported them to be TSPCs. ⁷⁸ The exact role of TSPCs in tendon maintenance and healing is not completely understood. Hence, there is a great need for in vitro and in vivo studies demonstrating their role and precise locations. ⁷²

OPEN IN VIEWER

Figure 4.

Location of different cells in tendon tissue. TSCs type I (orange) reside in the outer layer of the tendon (paratenon), TSCs type II (purple) reside in a niche in the inner part of tendons, and TNCs (brown) are aligned between fibres. Some of these subpopulations might overlap with each other, and perivascular TSCs may be present in the endotenon and peritenon (image partially created with https://www.biorender.com/).

OPEN IN VIEWER

Figure 5.

Differentiation of a TSPC to a tenocyte. The expression profile of a TSPC changes during differentiation to a tenocyte. Tenogenic differentiation is mostly driven by TGF-β2/3 and BMP12/13. Adapted from Schneider et al. ⁷⁴ (image partially created with https://www.biorender.com/).

Tendon mechanical properties

The characteristic tendon fibrillar ECM has distinct structural and biomechanical properties that facilitate the effective transmission and absorption of cyclical tensile forces while avoiding injury. These properties arise from the specialized axial and longitudinal structural organization of the collagen fibre hierarchy, which provides a scaffold for cell and macromolecule attachment. The tendon is primarily a uniaxial force-transmitting connective tissue consisting of bundles of parallel fibrillar ECM and resident tenocytes, which connect bone to muscle. ⁷⁸ Both the structure and the function of this fibrillar ECM provide biochemical and mechanical signals that cooperate in the integrated regulation of tenocyte proliferation, survival, differentiation and migration, which ultimately feedforward to maintain physiological ECM synthesis and assembly. The main purpose of collagen fibres is to resist tension, while the proteoglycans provide viscoelastic properties for the tendon. In addition to binding the fibres together, the endotenon enables fibre groups to glide over each other and carries blood vessels, nerves, and lymphatics to deeper portions of the tendon.

The initial portion of the stress-strain curve of a tendon is highly viscoelastic with a high viscous dissipation occurring during collagen fibril alignment. ¹⁰ Depending on the type and anatomical location of the tendon, this wavy fibril pattern results in different initial mechanical properties arising from the varying angle and length of ‘crimping’. ⁷⁹ When the tendon is stretched to higher strain levels, the stiffness of the material increases rapidly as the collagen fibres are recruited, straightened, and begin to carry a major part of the load; the tendon demonstrates the transition from the toe region to the linear region in which the strain is kept below 4% and the slope of the curve is defined by Young’s modulus, which represents tendon stiffness. In the linear region of the stress-strain curve, the tendon extension and force are directly proportional to one another. The stress generated by the fibre is a function of the number of fibres available to share the load. In the third phase, all collagen fibres are straight, and the system exhibits its highest stiffness. After this stage, a decrease in the stiffness of tissue is observed, the result of a gradual mechanical failure of the collagen fibre (Figure 6).

OPEN IN VIEWER

Figure 6.

Stress–strain relationship in tendons. At low levels of stress, tendons stretch relatively easily. This is called the ‘toe’ portion of the stress–strain curve, a consequence of straightening of crimped collagen fibrils and orientation of fibres along the direction of the applied load. With higher levels of stress, the highly oriented collagen fibres respond with a linear level of strain. The slope of the linear region represents the elastic modulus of the tendon. Continuing increases in the level of stress applied to tendons and ligaments lead to irreversible changes at the interface between collagen fibres in the structure.

Tissue substructures across size scales have been investigated to evidence their mechanical properties. However, the characterization of these structures outside the body, in a laboratory setting, reduces the clinical applicability of the results obtained. ⁸⁰ The fact that fibres are not stress-free constitutes an additional difficulty in the modelling of soft tissues since the strain is measured with respect to a stress-free configuration that does not exist physiologically. ⁸¹ This stress is developed in the absence of external loads, and it is known as residual stress. Modelling residual stresses is challenging, but it is of great importance, as the material and structural properties of soft tissues can be under or over-estimated.^82,83

The development of residual stresses is linked to cellular processes. ⁸⁴ These biological processes are a consequence of the continuous interplay between genetics and epigenetic factors. Epigenetic changes are related to the cell’s environment, and they include chemical agents and mechanical loading. Although cells contain genetic information about the structural patterns of the tissue, mechanical stimuli can condition the genetic instructions stored in the cells. ⁸⁵

Cyclic uniaxial mechanical loading of TSCs has demonstrated that proliferative capability increases and a loading magnitude-dependent differentiation effect has been observed, promoting either symmetric or asymmetric division. ⁸⁶ In the symmetric division, TSCs divide into two identical daughter cells, in the asymmetric one instead, one daughter cell is identical to the original one (self-renewal) while another becomes specialized. These observations can potentially explain how TSCs play a key role in tendinopathy development by undergoing aberrant, non-tenocyte differentiation under excessive mechanical loading conditions. ⁸⁷ When considering the uniaxial loading conditions of tendons, it has been demonstrated that tenocytes increase proliferation as well as tenogenic gene expression and protein production (Col I, Col III, TNMD, TNC-C, MMPs) in a stretching magnitude-dependent manner.^86,88,89

Scx has a well-defined role in the development of tendons during embryogenesis as a promoter of type I collagen production. A further key protein involved in various processes, such as tenocyte proliferation, collagen organization and fibril maturation is Tnmd. Mechanical forces regulate the expression of Scx through activation of the TGF-β-/Smad2/3-mediated pathway, which, in turn, is required for the maintenance of tendon-specific ECM. ⁹⁰ In contrast, the expression of tendon-associated markers may not be influenced by applied loading protocols. ⁹¹ In particular, there were no significant changes in Scx and Tnmd expression after loading conditions. Instead, an unexpected expression of Runt-related transcription factor 2 (Runx2), which is associated with osteogenic differentiation, has been observed. Moreover, the expression of Col1A1, Col3A1 and MMP2/3 was not upregulated in loading conditions. The resulting discrepancy can potentially be attributed to the different loading regimens used in the respective protocols. Indeed, the response of tendon cells to adapt by anabolic or catabolic processes depends on the applied frequency, magnitude, duration, and direction, all parameters applied differently by different authors.

To test whether mechanical loading of the tibia-induced molecular processes can lead to degeneration, the expression of the differentiation markers Lpl, Sox9 and Runx2 were examined as surrogates for adipogenic, chondrogenic and osteogenic differentiation, respectively. ⁹² In mice, treadmill running accelerates TSC proliferation in an intensity-dependent manner. However, although the expression of Tnmd and Col1A1 was not significantly increased in the intensive and moderate treadmill running groups, the intensive running group showed up-regulation of non-tenocyte-related genes Lpl, Sox9 and Runx2. The in vivo results were confirmed also by the in vitro experiments: after 8% stretching, up-regulation of the non-tenocytes-related gene was evident. This study analysed the gene expression of MGF, an Eb form of OGF-1, a growth hormone that promotes tissue growth. A higher level of the MGF gene was expressed in tendons after moderate loading, and more after intense activity, probably related to the higher mechanical load and larger extent of ‘micro-injury’. These findings indicate that more TSCs are generated for the repair and/or remodelling of tendons in response to the demands of mechanical loads. Specifically, under mechanical loading conditions, the TSCs population in the tendon grows, providing progenitors for tenocytes and enhancing the remodelling of tendons. This may explain why appropriate moderate exercise induces anabolic effects on the tendons, including enlarged cross-sectional area, increased tendon stiffness, and enhanced tendon tensile strength. On the other hand, intense mechanical loading still enhanced MGF expression, TSCs proliferation, and increased tenocyte-related gene expression, but it can also induce degenerative changes by inducing aberrant differentiation of TSCs into non-tenocytes, which, at later stages, manifests as lipid deposition, increased number of proteoglycans, and calcified tissue in the affected tendon. ⁹³

Other important actors in tenocyte mechano-transduction are cytokines and integrins. Cytokines, such as interleukins (IL), tumour necrosis factor-α (TNF-α), and interferon-gamma (IFN-γ) are known to be key players in tendon disorders.^94–97 They are released by the tendon stroma or immunoregulatory cells in response to mechanical stress or tissue injury, alter the cellular phenotype and induce changes in matrix production.^98,99 Adequate mechanical stimuli play an essential role in tendon homeostasis, regular function, tenocyte survival and tendon healing and mechanical factors influence tendon cytokine profile. ¹⁰⁰ An increased amount of pro-inflammatory cytokines such as IL-1a, IL-1b, TNF-α and IFN-γ was demonstrated in inflamed native equine tendon. ¹⁰¹ Over-mechano-stimulation of tendon and tenocytes leads to cytokine release such as IL-1b. ¹⁰² Stress deprivation and absence of mechano-stimuli induced cytokine over-expression (particularly that of IL-1b, TNF-α and other cytokines such as TGFβ) and mechanical deterioration of the tissue in the patellar tendon. ¹⁰³ Ruptured tendons revealed less TNF-α expression when naturally loaded during the healing process compared with unloaded ruptured tendons in a rat Achilles tendon healing model. ¹⁰⁴

Integrins are cell surface receptors known to connect the ECM to the actin cytoskeleton and transmit mechanical stimuli into the cell to evoke different cell responses. The collagen-binding Itga1 and Itga2 were both downregulated in vivo following 8% mechanical loading, ¹⁰⁵ confirming the key role of these molecules in mechano-transduction.

Tendon injury and healing

When a tendon is injured, its structure is disrupted, and proper function can be compromised. Unfortunately, tendon injuries are a common clinical problem, and they are broadly categorized as chronic tendinopathies or acute ruptures. ¹⁰⁶

On one end of the spectrum is chronic tendinopathy, initiated by biological and physical factors that include ageing, oxidative stress, and repetitive loading during intensive exercise. ¹⁰⁷ Indicators of chronic tendon injury range from pain, inflammation, and increased cross-sectional area to histologically observable changes including increased proteoglycan content, increased cellularity, hypervascularity, ectopic bone, cartilage nodules and disorganization of the collagen-fibril network.^108,109 On the other end of the spectrum lie tendon ruptures. ¹¹⁰ Although this type of injury may be spontaneous or induced by direct trauma and/or excessive loading, most tendon tears are preceded by histological changes consistent with chronic tendinopathy, suggesting that tendon rupture is closely associated with degeneration, ¹¹¹ though in these patients the tendinopathic changes generally remain clinically silent until the condition is manifested through an acute rupture. Investigations of tendon healing have been predominantly undertaken on transected animal tendons, and it is unclear how relevant they are to the healing of tendinopathic or ruptured human tendons.

The response to a tendon injury and healing is classically considered to occur through extrinsic and intrinsic healing. ¹¹² In intrinsic tendon healing, the proliferation of epitenon and endotenon tenocytes takes place – Healing of the defect involves an exudative and a formative phase which, overall, are very similar to those associated with wound healing. ¹¹³ Extrinsic healing occurs through chemotaxis of the specialized fibroblasts into the defect from the ends of the surrounding tendon sheath and, if present, synovium. ¹¹⁴ The process can be divided into three overlapping phases: inflammation, repair and organization or remodelling^111,112 (Figure 7).

OPEN IN VIEWER

Figure 7.

Key molecular, cellular and matrix changes occurring during the three main phases of tendon repair. Each healing stage is characterized by the involvement of different growth factors, activation of specialized cell types, and production of essential matrix proteins. Collectively, they contribute to the replacement of the initial fibrous tissue with more tendinous regenerated. Adapted from Docheva et al. ⁷¹ and James et al. ¹¹⁵

In the inflammatory stage, which typically spans a few days after the injury, the wound site is infiltrated by red blood cells, white blood cells (leucocytes), and platelets secreting growth factors and endothelial chemoattractants. ¹¹¹ Cells migrate from the extrinsic peri-tendinous tissue such as the tendon sheath, periosteum, subcutaneous tissue and fascicles, and from the epitenon and endotenon. ¹¹⁴ A fibrin clot provides temporary stiffness and biomechanical stability, macrophages digest necrotic debris and tenocytes are recruited to the wounded area and stimulated to proliferate, particularly in the epitenon. ¹¹⁶

The second stage, the proliferative stage, begins roughly 2 days into the injury response. ¹¹¹ This phase of healing is characterized by profuse synthetic activity and is directed by macrophages and tenocytes. Macrophages, whose role shifts from phagocytic to reparative a few days after injury, ¹¹⁷ release growth factors and direct cell recruitment.^111,118 Meanwhile, tenocytes deposit a temporary, mechanically inferior matrix composed mostly of type III collagen. Tenocytes become the main cell type, and collagen is continuously synthesized over the next 5 weeks. During the fourth week, a noticeable increase in the proliferation of fibroblasts of intrinsic origin, mainly from the endotenon, takes place. These cells take over the main role in the healing process, and both synthesize and reabsorb collagen. The newly formed tissue starts to mature, and the collagen fibres increasingly align themselves along the direction of force through the tendon. This phase of repair continues for 2 months after the initial injury.^111,112

In the third and final stage, the remodelling phase, type I collagen synthesis begins to dominate, and the ECM becomes better aligned. In addition, cell density and general synthetic activity are gradually decreased. This phase begins 1–2 months after injury and can last more than a year. ¹¹¹

Numerous bioactive molecules are involved in orchestrating the cellular response during tendon repair. ¹¹⁹ A variety of growth factors are markedly upregulated following a tendon injury and are active at multiple stages of the healing process, including insulin-like growth factor-I (IGF-I), TGFβ, bFGF, platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), BMP and connective tissue growth factor (CTGF). ¹⁰⁶

Despite intensive remodelling over the following months, complete regeneration of the tendon is never achieved. ¹²⁰ The tissue replacing the defect remains hypercellular. The diameter of the collagen fibrils is altered, favouring thinner fibrils with a reduction in the biomechanical strength of the tendon. The repaired tissue appears scar-like, and never completely regains its pre-injury biomechanical properties. ¹¹¹ In tendinopathic and ruptured Achilles tendons, there is a reduction in the proportion of type I collagen, and a significant increase in the amount of type III collagen, ¹²¹ responsible for the reduced tensile strength of the new tissue as a result of a reduced number of cross-links compared with type I collagen. ¹²² Recurring micro-injuries lead to the development of hypertrophied biologically inferior tissue replacing the intact tendon. ¹¹²

Current status for enhancement of tendon healing and replacement

First-line therapeutic options differ for chronic and acute tendon injuries. The primary goal of tendinopathy treatment is to reduce pain, with a combination of exercises, physical therapy modalities and local and systemic pharmacological agents,^123,124 whereas surgical techniques aim to repair ruptured tendons.^71,125

The approach to treatment in acute soft tissue trauma relies heavily on the patient’s history, signs, and symptoms including the grade of injury, and their physical and work activities goals after therapy. Initially, clinical evaluation determines the grade of injury and the level of instability in the joint. Imaging (ultrasound and magnetic resonance imaging) assists in the diagnosis, after which the patient is considered for conservative or surgical treatment. ¹²⁶

In the case of surgical treatment, the outcomes of reconstructive surgery differ depending on the type and location of the injury. The type of suture may also play a critical role in the strength of repair and tendon autografts may be used to facilitate tendon reconstruction, particularly in cases involving tendon loss or retraction. ¹²⁷ Autografts have many advantages, such as the absence of immunological complications, rapid incorporation, and good remodelling. However, autografts also present some disadvantages, such as increased duration of operation given the time necessary for graft harvest and preparation; limited donor tendon sources; and sacrifice of the function of the donated tendon. Moreover, the neo-tendon repaired by autograft is not identical to the normal tendon and may take a long time to remodel. ¹²⁸ It should be acknowledged, however, that tendon appearance post-operatively may well exert no influence on its function. ¹²⁹

For both chronic and acute tendon injuries, exercise-based rehabilitation is indicated. ⁷⁴ Eccentric exercise therapy (involving active lengthening of muscle and tendon) has become the first-line treatment and is considered the most efficient for tendinopathy (e.g. Achilles and patellar tendon). Good-quality randomized controlled trials indicate that eccentric strengthening programmes provide 60%–90% improvement in pain and function. ¹²⁸

Mechanical loading is also integrated into clinical postoperative rehabilitation protocols. The mechanical stimulation from controlled mobilization is suggested to enhance tendon repair and remodelling by stimulating tenoblast activities (such as fibroblast proliferation and collagen synthesis and realignment), leading to increased tensile strength, increased tendon diameter and fewer adhesions compared with immobilized healing tendons.^130,131 In contrast, immobilization following tendon injury may have a negative effect on tendon healing, as evidenced by lower tensile strength and lower strain at failure compared with control samples. ¹³² Immobilization also reduces the water and proteoglycan content of tendons and increases the number of reducible collagen cross-links. ¹³³

The use of autologous growth factors is another therapeutic approach, which is gaining popularity in the treatment of tendon injury. Platelet-rich plasma (PRP) is a blood derivative containing high levels of growth factors, known to promote tissue healing. ¹³⁴ Because PRP is readily available and autologous, PRP therapy is considered safe and has been introduced into a clinical therapy for tendinopathy and acute tendon injury. However, the benefits of PRP injection for tendon recovery remain controversial. ¹³⁵ Extracorporeal shockwave therapy has demonstrated efficacy in randomized controlled trials^136,137 and register studies ¹³⁸ ; less conventional procedures, such as phonophoresis, therapeutic ultrasonography or low-level laser therapy, are other options for the treatment of tendon injuries.^125,139

Consequently, surgery, specific exercise-based therapy, and autologous growth factor injections are the main current treatments for tendon injuries. Unfortunately, independently of the procedure of management of tendon injury, the outcomes of both conservative treatments and surgical repair require long healing time, high re-rupture rate and scar tissue formation. ⁸ In addition to being moderately effective or controversial, the underlying mechanisms of these treatments are not fully understood. ¹⁴⁰

Future prospective in regenerative medicine of the tendon

Tissue engineering has now emerged as a potential alternative to tissue or organ transplantation, which involves delivering cells or therapeutics to diseased or damaged tissue to restore tissue or organ function. ¹⁴ With this technology, tissue loss or organ failure can be treated by implantation of a tissue-engineered graft composed of some or all the three major components: cells, biomaterials/scaffold, and biomolecules (e.g. growth factors, cytokines, nucleic acids, etc.) into sites of need. ¹²⁸

A key factor in the tissue engineering approach to repair and regeneration is the availability of appropriate cells. Cell availability is crucial to access their proliferation potential, cell-to-cell signalling, bio-molecule production, and formation of extracellular matrix. Stem cells have attracted great interest in tissue engineering given their intrinsic differentiation capacity and expansion potential. ¹⁴¹

Of the various stem cell types that are available for tendon and tendon-bone junction repair, mesenchymal stem cells (MSCs) are an attractive cell source as they have high proliferative potential and can differentiate into various cell types of the mesodermal lineage. ¹⁴² The transplantation of mesenchymal stem cells (MSCs) has been reported to improve tendon, ligament and tendon-to-bone junction repair.^141–145 MSC therapeutic area of the tendon has been focusing on specific tendon sites including the rotator cuff tendon and superficial digital flexor tendon (SDFT). Intervention through direct injection of umbilical cord-derived MSCs (UC-MSCs) has been shown to promote the healing of rotator cuff tears in rabbit. ¹⁴⁶ Furthermore, a single administration of adipose tissue-derived MSCs (AT-MSCs) also positively affects the collagen crosslinking and remodelling of scar tissue in SDFT lesions. ¹⁴⁷ Improved neovascularization during tendon healing could also be observed when horses were injected with AT-MSCs for SDFT repair. ¹⁴⁸

However, MSCs-like populations have now been identified from tendon tissues of various species including humans, rabbits, rats, and horses, in vitro.^73,149–151 These tendon stem cells (TSCs) largely meet the MSC definition of the International Society for Cellular Therapy (ISCT), ¹⁵² which is based on three criteria: adherence to plastic, specific antigen (Ag) surface expression (CD73, CD105 and CD90) and multipotent differentiation potential (through trilineage differentiation). TSCs can effectively promote the repair and regeneration of injured tendons.^{90,145,153,154} Isolated from tendon tissue, the use of tendon stem cells for tendon and tendon-bone junction repair ¹⁵⁵ might be advantageous since the tendon milieu is the originating environment, which may promote engraftment and differentiation of the transplanted cells. ¹⁴²

Stem cells retain self-organization capabilities. ¹⁵⁶ Self-organization depends on cells’ intrinsic ability to recognize, process, and react to a wide range of global and local cues, such as morphogen gradients, ¹⁵⁷ mechanical boundary conditions ¹⁵⁸ or cellular proliferation and environmental remodelling. ¹⁵⁹ As a result, self-organization is stimulated by developing microscale interactions that together lead to macroscale alterations. This suggests that it should also be possible to use the cell’s self-organization capacity outside of an organism, that is, in vitro, by providing an ideal and permissive environment and by including crucial spatiotemporal cues to drive multicellular responses. ¹⁶⁰ Together with self-organization, the ability of stem cells to self-renew and differentiate into distinct cell types from various lineages is a special quality that has been used to mimic the characteristics of organogenesis in cell culture. However, exogenous signals, like inductive growth factors, such as bone morphogenetic proteins^81,161 (BMPs), transforming growth factor (TGF)-β and basic fibroblast growth factor ¹⁶² (bFGF), are still required to guide cell self-organization and differentiation to obtain proper patterning. For this reason, the employment of specifically engineered cell instructive materials can be extremely beneficial. Indeed, the incorporation of adhesion ligands, such as RGD and YIGSR, within a number of hydrogel matrices (e.g. alginate, collagen, fibrin or PLA/PLGA ¹⁶³ and PCL) has provided the capacity to enhance certain cell-material responses and to increase cell survival and differentiation. ¹⁶⁴

Moreover, it appears that the effects of MSCs are mainly mediated by paracrine mechanisms and by the secretion of extracellular vesicles (EVs). Consequently, there is a growing interest in the clinical applications of EVs, ¹⁶⁵ which have the potential to be used clinically in a variety of different ways such as pharmacological delivery agents, non-invasive biomarkers for early diagnosis, and biological reagents to treat diseases as well as to enhance tissue repair and regeneration. ¹⁶⁶

A biophysical approach to induce MSCs differentiation into tenocytes

Hierarchical anisotropy structures directing 3D cellular orientation play a crucial role in designing tendon tissue engineering scaffolds. As previously reported, surface nanopatterning can control the initial assembly of focal adhesions, hence guiding human mesenchymal stem cells (hMSCs) through the process of self-organization and differentiation. ¹⁵⁶ This process self-sustains, leading to the development of macroscopic tissues with molecular profiles and microarchitecture reminiscent of embryonic tendons.

Autologous or allogenic tendons for tendon reconstruction have routinely been applied for medical treatment, with relatively good outcomes: however, these materials encounter several problems. ¹⁵³ For this reason, a medical strategy able to reconstruct tendon ruptures involving the development of artificial tendon-like tissue with tendon-like mechanical and histological properties from human tendon cells in vitro is required. Among the multiple biochemical and biophysical cues of the tendon niche, the ECM architecture plays a key role in governing tendon cell behaviour. ¹⁶⁷ This underlines the importance of tendon mimetic topography on mesenchymal stem cell commitment towards a tenogenic phenotype.

While a variety of stem cells have been investigated for biomedical applications, Mesenchymal Stromal/Stem Cells are of particular interest. MSCs are multipotent stromal cells able to differentiate into several cell types. Additionally, MSCs have excellent accessibility and plasticity and promote paracrine effects. Since they can be extracted from adult tissue, mainly bone marrow and adipose tissue, they are free from ethical concerns. ¹⁰ Bone marrow is the most widely recognized source of MSCs, but recent research has identified alternative sources of MSCs-like cells, and it has been suggested that MSCs may be present virtually in any vascularized tissue throughout the whole body. ¹⁶⁸

MSCs are considered immunoprivileged, given their lack of expression of several surface antigens important for T- and B-cell recognition and their capability to suppress lymphocytes. ¹⁶⁹ Another benefit of MSCs is that they can exert a positive influence on various blood cell types leading to an anti-inflammatory milieu during tissue repair by suppressing tissue necrosis factor (TNF)-α and interferon (INF)-γ, while stimulating the expression of suppressive cytokines like interleukin (IL)-10. ¹⁷⁰ hBM-MSCs displayed tenogenic differentiation under the combination of bone morphogenetic proteins and/or mechanical stimulation. ⁶⁸

However, as stated, BMSCs also have some limitations, such as painful harvesting procedures and a frequent low cell yield, reduced MSCs quality with advanced donor age, ectopic ossification, and higher risk of adhesion formation when transplanted in vivo. ¹⁷¹ As the bone marrow niche contains numerous differentiated and progenitor cell types, studying the properties of MSCs in vivo is challenging. In addition to the contamination of other cell types, there is wide variation among donors, and even between different harvesting sites in the same donor. Primary MSCs cultures often display differing growth kinetics and variations in the proportion of cell populations therein. Such variability produces challenges in obtaining consistent phenotypic and functional results and may lead to incorrect interpretation of data. ¹⁷² It should always be considered that, depending on the desired use of MSCs in distinct tissue injury treatments, the isolation protocol would need to be set up and specifically optimized to obtain MSCs with the most optimal biological properties and therapeutic potential. This should be considered in the context of the immunomodulatory properties of MSCs cultured in different microenvironments. The application of MSCs is still limited, considering, for example, the need to produce enough cells from a single donor, avoiding the senescence of the cells and the loss of therapeutic efficacy. Therefore, the promotion of cell proliferation while retaining MSC stemness in the early stages of primary cultivation is crucial. To address this issue, attempts have been made to simulate the stem cell niche in vitro.

One of these approaches has been the application of what is frequently termed reduced oxygen or hypoxia during MSC culture.^173,174 More specifically, we can use the term physoxia to refer to the natural level of oxygen present under in vivo conditions. Physoxia could be applied to MSCs in vitro to recapitulate the influence of native local signals on the differentiation or proliferation of these. ¹⁷⁵ In certain types of adult stem cells (human urine stem cells, dental pulp stem cells, amniotic fluid stem cells and bone marrow stromal cells), a low oxygen concentration in vitro promotes the proliferation and maintenance of a multipotent state.^175,176 Conversely, other investigators have demonstrated hypoxia to be a potent stimulus for differentiation into specific cell lines.^177,178 Independently, alteration in the oxygen concentration represents a physiological stimulus, which triggers intracellular mechanisms responsible for cell death, differentiation, or cell adaptation to new environmental conditions.

Hypoxia canonically leads to the stabilization and induction of Hypoxia-inducible factor 1-α within the cells. This protein strongly influences the metabolism, proliferation, and multipotency of MSCs. It rapidly degrades upon removal of the hypoxic condition, as the degradation of the protein is oxygen dependent, with a half-life of less than 1 min. This short half-life affects the stability and expression levels during exposure to ambient air oxygen concentration and, also, during the usual cell culture routine. Moreover, hypoxic cell culture conditions may lead to a decrease in the extracellular pH (extracellular acidosis). The latter can lead to the maintenance of stemness and attenuation of the differentiation potential of MSCs. ¹⁷⁹

Analysis of the metabolic activities of MSCs under hypoxic conditions indicates an increase in the consumption of glucose and glutamine and the production of lactate as a consequence of switching cell metabolism from oxidative phosphorylation to anaerobic glycolysis. ¹⁸⁰ This shift is associated with a reduced mitochondrial transmembrane potential. ¹⁸¹ A direct consequence of this metabolic activity is the increase in proliferative activity and the enhanced ability to form CFU-F. Further, an up-regulation of stemness gene expression is observed, such as Oct-4, C-myc, Nanog, Nestin and HIF-1α.^175–182 Thus, it is possible that long-term in vitro hypoxia enhances a genetic programme that maintains the MSCs in an undifferentiated state and in parallel stimulates the expression of genes involved in the development of various cell lines.

In vivo, MSCs are integrated into specific tissue niches where their homeostasis is regulated by a balanced set of physiochemical factors,^183,184 while in vitro only a small number of these can be simultaneously replicated. In this context, hierarchical anisotropy structures directing 3D cellular orientation play a crucial role in designing tendon tissue engineering scaffolds. As previously reported, surface nanopatterning can control the initial assembly of focal adhesions, hence guiding human mesenchymal stem cells (hMSCs) through the process of self-organization and differentiation. ¹⁵⁶ This process self-sustains, leading to the development of macroscopic tissues with molecular profiles and microarchitecture reminiscent of embryonic tendons.

The role of EVs in tendon healing

Extracellular vesicles (EVs) are diverse, nanoscale membrane vesicles actively released by cells of all tissues and organs in both health and pathologies. ¹⁸⁵ Similar-sized vesicles can be further classified (e.g. exosomes, microvesicles) based on their biogenesis and biophysical properties. Although initially thought to be cellular debris, and thus under-appreciated, EVs are now increasingly recognized as important vehicles of intercellular communication and circulating biomarkers for disease diagnoses and prognosis. ¹⁸⁶

EVs are produced by all cell types and cross biological membranes/barriers to deliver payloads to target cells and organs. EVs contain surface receptors, membrane and soluble proteins, lipids, ribonucleic acids (mRNA, microRNA, tRNA, rRNA, small nucleolar RNA, small circular nucleolar RNA, piRNA, scaRNA, viral RNA, Y RNA and long non-coding RNA),^187–190 and even genomic and mitochondrial DNAs.^190,191 The native cargo delivery capacity of EVs has been exploited for use as drug delivery vehicles, as they are immune-compatible, noncytotoxic and non-mutagenic compared with existing viral or cellular-based therapies. ¹⁷⁷ EVs are highly dependent on the origin and functional status of the parent cell since they reflect their phenotypic state.^14,192 For example, EVs derived from umbilical progenitor cells have proangiogenic effects, ¹⁹³ while platelet-derived EVs are most abundant in circulation and help to activate platelets and the formation of fibrin clots. ¹⁹⁴

Recent investigations revealed the potential therapeutic benefits of using MSC-derived EVs for tendinopathies and tears.^8,195 The use of MSC-EVs as a potential therapeutic strategy for the treatment of tendon and ligament disorders has many advantages compared to cell-based therapies, including low immunogenicity, removal of the need to maintain cell viability, removal of the risk of uncontrolled proliferation and differentiation of implanted cells, and no risk of persistence from permanent grafts upon the cessation of therapy. Furthermore, MSC-EVs can be used directly, either alone or in combination with other pharmacological agents, to enhance treatment effects. The cell-targeting effects of MSC-EVs also distinguish them from other synthetic nano-vesicles and thus potentiate their role as a drug delivery nano-platform. ⁸ A better understanding of the mechanisms underlying the actions of MSC-EVs on the promotion of tendon repair would facilitate the development of MSC-EVs as a new therapeutic strategy for the treatment of tendon disorders. ⁸

The literature displays three prevailing methods of healing ¹⁴ : increased proliferation, migration and tenogenic differentiation of tendon stem cells (TSCs) and tenocytes, ¹⁹⁶ attenuating inflammatory responses, ¹⁹⁷ and improving the tendon–bone interface. ¹⁹⁸ The EVs act by the following mechanisms ¹⁴ (Figure 8).

OPEN IN VIEWER

Figure 8.

EVs mechanism of healing for tendinopathies. Schematic diagram showing the three major categories of the increasing proliferation of tenocytes, attenuation of the inflammatory response, and improvement in enthesis to explain the mechanism of healing. Adapted from Fang et al. ¹⁴

Conclusion

Tendon injuries are a common clinical problem that results from overuse, genetic predisposition, tears, or ageing. More than 30 million tendon injuries occur annually worldwide. ²¹⁰ Tendon injury is currently managed by two approaches: (1) conservative treatment which aims to relieve pain and (2) surgical exploration, with excision and/or repair. Irrespective of the approaches used, the full restoration of tendon functions is challenging considering the high mechanical loads they are subjected to and the low cell density and vascularization that hamper the synthesis of extracellular matrix. Repeated ruptures, joint stiffness, and restricted movement are common problems encountered even after repair. ¹⁴¹

The inability of the tendon to self-repair and the inefficiency of current treatment regimens have sparked the exploration of alternative treatment strategies. ¹⁴¹ Biological augmentation and tissue engineering approaches are promising avenues of nonsurgical treatment presently explored. ¹⁴ They consist mainly of applying growth factors, singly or in combination, stem cells in native or genetically modified form, and biomaterials, alone or cell-loaded, at the site of tendon damage ⁷¹ to try to regain original tissue or organ structure and function. From the biological point of view, the implementation of a tissue-engineered tendon is based on two main steps: the finding of precursors/progenitors based on their origin and localization and the commitment and differentiation based on pivotal signalling cascades. Mesenchymal stem cells have shown great potential within regenerative medicine exhibiting differentiation capability when exposed to soluble signals like growth factors.^67,211–213

There are mainly two problems that researchers face during the regeneration of tendinous tissues. One is to achieve the generation of a highly specialized and three-dimensional organized matrix, whose formation implies not only biological but also mechanical constraints. The second challenge is to prevent inappropriate plasticity of exogenous cells, or trans-differentiation of the local tenocytes into undesirable lineages leading to, for example, in situ adipose, cartilaginous, or bone tissue formation. ⁷¹ To facilitate the transmission of the right signal to cells, researchers are increasingly studying the potential of EVs, which perform the role of mediators of intercellular communication by conveying biological information between cells.

Tendon tissue engineering seeks to provide alternatives to autograft by exploiting a biocompatible material that acts as a scaffold for cell reprogramming and in vivo tissue remodelling to fabricate a tendon-like tissue. ²¹⁴ Implementing EVs enriched three-dimensional scaffolds could aid in guiding and controlling cell orientation, ultimately enabling to obtaining of anisotropic tissues in vitro. Therefore, cell response results from the elaboration of multiple signals that come from the material and the de novo synthesized matrix whose structure and composition constantly change in time and space owing to cell activity. Engineering artificial platforms intended to sustain tissue production in vitro must consider the dynamic structural and compositional changes of the system. The array of signals embossed on the material surface constitutes the initial condition from which cell-cell and cell-matrix interactions establish and guide the evolution of the cells’ differentiation path.

Through examination of the results of in vivo and in vitro experiments, stem cell EVs can be considered as early diagnostic and prognostic biomarkers, as well as novel, targeted therapeutics, and drug carriers for various diseases, such as myocardial infarction, burns, and pulmonary fibrosis, with superior results, compared to using stem cells exclusively.^8,215 Furthermore, bone marrow MSCs, TSCs and tenocytes EVs can promote macrophage polarization at the site of tendon-bone injury to eliminate inflammation, strengthen the formation of fibrocartilage to improve biomechanical properties and enhance cell proliferation, migration and tenogenic differentiation of tendon stem cells and tenocytes. ²¹⁶